ABSTRACT
Patients on warfarin and their physicians must constantly balance the risks of bleeding and clotting. We offer practical tips for safe and effective warfarin therapy, based on the practices of the Anticoagulation Clinic of The Cleveland Clinic.
Footnotes
↵* The author has indicated that he is on the speakers’ bureau of the Bristol-Myers Squibb (formerly DuPont Pharmaceutical) and Aventis corporations. He is also a consultant to Aventis and AstraZeneca and has received grant or research support from AstraZeneca.
† The author has indicated that he has received grant or research support from DuPont Pharmaceuticals.
- Copyright © 2003 The Cleveland Clinic Foundation. All Rights Reserved.
Jump to section
Related Articles
Cited By...
- A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various CYP2C9 Genotypes under Different Cotreatments
- Whole genome sequencing identifies high-impact variants in well-known pharmacogenomic genes
- Painful Reality: Inappropriate Provider Management of Pain as a Determinant of Health Care Avoidance
- Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation